Emerging Oral Solid Dosage Contract Manufacturing Market Trends: Companies In Oral Solid Dosage Contract Manufacturing Market Focus On Innovative Solutions To Stay Competitive Shaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Oral Solid Dosage Contract Manufacturing Market Size Growth Forecast: What to Expect by 2025?
Recent years have seen significant growth in the oral solid dosage contract manufacturing industry. The market size is projected to increase from $39.39 billion in 2024 to $42.51 billion in 2025, representing a compound annual growth rate (CAGR) of 7.9%. Factors such as a growing world population, increasing incidence of chronic diseases, and an enhanced emphasis on research and development have all contributed to this historic period of growth.

How Will the Oral Solid Dosage Contract Manufacturing Market Size Evolve and Grow by 2029?
The market for oral solid dosage contract manufacturing is predicted to witness substantial growth in the ensuing years, with its size estimated to reach $56.89 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.6%. Expected growth during this forecast period can be credited to the rising trend of outsourcing in pharmaceutical companies, advancements in drug delivery systems, and escalated activities in drug development. Key trends observed in the forecast period encompass developments in drug delivery techniques, the incorporation of 3D printing, and progress in controlled-release technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-contract-manufacturing-global-market-report

What Drivers Are Propelling the Growth of Oral Solid Dosage Contract Manufacturing Market Forward?
The growth of the oral solid dosage contract manufacturing market is expected to be fueled by the rising demand for generic drugs. These are medications that are bioequivalent to branded drugs in terms of dosage, strength, safety, efficiency, quality, and use. Factors such as the expiration of patents, efforts to contain costs, regulatory incentives, and increased healthcare access are attributed to the growing demand for these drugs. The production and distribution of generic drugs are significantly assisted by oral solid dosage contract manufacturing. This is achieved by leveraging the expertise of contract manufacturers to improve operational efficiency, reduce costs, ensure high-quality production, and expedite the product's market entry. In 2022, as reported by the Food and Drug Administration, a federal agency based in the US, it was estimated that 91% of all prescriptions in the US were filled with generic drugs, with the FDA approving over 32,000 generic drugs. Therefore, the demand for generic drugs is a key driver for the growth of the oral solid dosage contract manufacturing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16137&type=smp

Which Emerging Trends Are Transforming the Oral Solid Dosage Contract Manufacturing Market in 2025?
Firms dominating the market for contract manufacturing of oral solid dosage are putting efforts into inventing cutting-edge solutions such as continual production lines to maintain their stance in the industry. A continual manufacturing line represents a production system that uses ongoing production methods to create pharmaceuticals or other goods. Take, for example, in January 2023, a Chinese pharma-family giant, WuXi STA, unveiled its debut continual production line for oral solid pharmaceutical goods. This ultra-modern facility represents a significant milestone in the realm of pharmaceutical manufacturing, utilizing the principles of continuous manufacturing to boost efficiency, quality, and flexibility in the drug production process. This adaptability facilitates the manufacturing process timelines and minimizes downtime, ultimately accelerating the distribution of essential medicines to patients.

What Are the Key Segments in the Oral Solid Dosage Contract Manufacturing Market?
The oral solid dosage contract manufacturing market covered in this report is segmented -

1) By Product Type: Tablets, Capsules, Powders, Granules, Other Product Types
2) By Service: Drug Product Development, Fill Finish Product Manufacturing, API Manufacturing, Packaging And Labelling, Other Applications
3) By Therapeutic Area: Oncology, Cardiovascular Diseases, Metabolic Disorders, Neurological Disorders, infectious Diseases, Gastrointestinal Diseases, Other Therapeutic Areas
4) By End User: Large Size Companies, Medium And Small Size Companies

Subsegments:
1) By Tablets: Compressed Tablets, Effervescent Tablets, Chewable Tablets, Coated Tablets (Enteric, Film Coated), Sustained Or Controlled Release Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Vegetarian Capsules, Liquid-Filled Capsules, Delayed Release Capsules
3) By Powders: Powders For Oral Suspension, Powders For Direct Compression, Powders For Mixing Or Blending, Instant Dissolving Powders
4) By Granules: Granules For Direct Compression, Granules For Tabletting, Effervescent Granules, Delayed Or Controlled Release Granules
5) By Other Product Types: Lozenges, Oral Strips, Oral Thin Films, Effervescent Tablets Or Granules

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16137&type=smp

Who Are the Key Players Shaping the Oral Solid Dosage Contract Manufacturing Market's Competitive Landscape?
Major companies operating in the oral solid dosage contract manufacturing market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Siemens Healthineers AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under the CordenPharma brand, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation

What Geographic Markets Are Powering Growth in the Oral Solid Dosage Contract Manufacturing Market?
Asia-Pacific was the largest region in the oral solid dosage contract manufacturing market in 2023. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16137

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.